Curaleaf Retracts CBD Health Claims After FDA Warning, New York Decriminalizes Cannabis: Week in Review
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) — PRESS RELEASE — Bragar Eagel & Squire, P.C. is investigating potential claims against Curaleaf Holdings, Inc. on behalf of Curaleaf investors. The investigation concerns whether Curaleaf has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 22, 2019, the FDA sent a warning letter to Curaleaf stating that several of the company’s CBD products sold on the company’s website were “misbranded drugs” in violation of the Federal Food, Drug, and Cosmetic Act.
On this news, Curaleaf’s stock price fell $0.54, or over 7 percent, to close at $7.40 per share on July 23, 2019.
If you purchased or otherwise acquired Curaleaf shares, have information, would like to learn more about these claims or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Curaleaf, please go to https://bespc.com/CURLF. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.
Published at Sat, 03 Aug 2019 14:00:00 +0000